TFF PHARMACEUTICALS, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-03-06: Form 8-K; Period of report 2025-03-03; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
- 2025-02-03: Form 8-K; Period of report 2025-01-28; Description 3.02 Unregistered Sales of Equity Securities; 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events; Details 3.02.
- 2024-12-10: Form 8-K; Period of report 2024-12-04; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2024-11-14: Form 8-K; Period of report 2024-11-14; Description 1.02 Termination of a Material Definitive Agreement; 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 1.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2025-03-06 | 8-K | 2025-03-03 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On March 3, 2025, TFF Pharmaceuticals, Inc. (“Company”) held a Special Meeting of Stockholders for the purpose of approving the dissolution of the Company in accordance with Section 275 of the Delaware General Corporation Law and the Plan of Dissolution previously distributed to the Company’s stockholders in connection with the Special Meeting (the “Plan of Dissolution”). | ea0233448-8k_tffpharma.htm |
| 2025-02-03 | 8-K | 2025-01-28 | 3.02 Unregistered Sales of Equity Securities; 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 3.02 On January 28, 2025, the Board of Directors (the “Board”) of TFF Pharmaceuticals, Inc. (the “Company”) authorized the issuance of 4,443,926 shares (“Special Shares”) of the Company’s $0.001 par value common stock (“Common Stock”) to Craig R. Jalbert, the Company’s Chief Executive Officer and sole director, for good and valuable consideration. 5.07 The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference. 8.01 On January 28, 2025, the Company convened its special meeting of stockholders (the “Special Meeting”) for the purpose of approving the liquidation and dissolution of the Company in accordance with Section 275 of the Delaware General Corporation Law (the “Dissolution”) and pursuant to the Plan of Dissolution attached to the proxy statement previously distributed to the Company’s stockholders in connection with the Special Meeting (the “Plan of Dissolution”) (the “Dissolution Proposal”). | ea0229695-8k_tffphar.htm |
| 2024-12-10 | 8-K | 2024-12-04 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On December 4, 2024, TFF Pharmaceuticals, Inc. (“Company”) received a determination letter (the “Delisting Notification”) from the Nasdaq Stock Market (“Nasdaq”) stating that the Nasdaq staff determined, in accordance with Nasdaq Listing Rules 5101 and 5110(b) and Nasdaq Listing Rule IM 5101-1, that the Company’s common stock will be delisted from The Nasdaq Stock Market. | ea0224167-8k_tffpharma.htm |
| 2024-11-14 | 8-K | 2024-11-14 | 1.02 Termination of a Material Definitive Agreement; 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.02 On November 14, 2024, the Board of Directors (the “Board”) of TFF Pharmaceuticals, Inc. (the “Company”) unanimously approved the dissolution and liquidation of the Company pursuant to a plan of dissolution (the “Plan of Dissolution”), subject to stockholder approval. 2.05 On November 14, 2024, in connection with the planned wind down of the Company’s operations, the Board of the Company unanimously approved a reduction-in-force (the “Reduction in Force”) of substantially all of its employees to be effective on November 15, 2024. 5.02 On November 14, 2024, in connection with the planned wind down of the Company’s operations, Harlan Weisman, M.D., Robert J. Mills, Stephen Rocamboli, Brandi Roberts, Catherine Lee and Thomas King, each notified the Company of their respective resignations as members of the Board and all committees thereof, effective November 14, 2024. | ea0221102-8k_tffpharma.htm |
| 2024-08-14 | 8-K | 2024-08-14 | 2.02 Results of Operations and Financial Condition | 2.02 On August 14, 2024, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2024. | ea0211390-8k_tffpharma.htm |
| 2024-08-06 | 8-K | 2024-08-06 | 7.01 Regulation FD Disclosure | 7.01 On August 6, 2024, the Company issued a press release and published an investor presentation on its website at https://tffpharma.com/investors/. | ea0210679-8k_tffpharma.htm |
| 2024-07-01 | 8-K | 2024-06-26 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 26, 2024, Michael Patane tendered his resignation from our Board of Directors effective as of June 30, 2024. | ea0208732-8k_tffpharma.htm |
| 2024-06-07 | 8-K | 2024-06-04 | 5.07 Submission of Matters to a Vote of Security Holders | ea0207541-8k_tffpharma.htm | |
| 2024-05-17 | 8-K | 2024-05-17 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | ea0206421-8k_tffpharma.htm |
| 2024-05-14 | 8-K | 2024-05-14 | 2.02 Results of Operations and Financial Condition | 2.02 On May 14, 2024, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024. | ea0206069-8k_tffpharma.htm |
| 2024-05-02 | 8-K | 2024-04-29 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On May 1, 2024, TFF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), completed a public offering (the “Offering”) of (i) 578,914 shares (the “Common Shares”) of its common stock, par value $0.001 per share (the “Common Stock”); (ii) pre-funded warrants (the “Pre-Funded Warrants”) exercisable for an aggregate of 1,086,305 shares of Common Stock (the “Pre-Funded Warrant Shares”); and (iii) Series B Warrants (the “Series B Warrants”) exercisable for an aggregate of 1,665,219 shares of Common Stock (the “Series B Warrant Shares”) issued pursuant to the securities purchase agreement, dated April 29, 2024 (the “Securities Purchase Agreement”), between the Company and certain institutional investors (the “Investors”). | ea0205128-8k_tffpharma.htm |
| 2024-04-29 | 8-K | 2024-04-29 | 7.01 Regulation FD Disclosure | 7.01 On April 29, 2024, the Company published a scientific presentation on its website at https://tffpharma.com/investors/. | ea0204832-8k_tffpharma.htm |
| 2024-03-28 | 8-K | 2024-03-28 | 2.02 Results of Operations and Financial Condition | 2.02 On March 28, 2024, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2023. | ea0202827-8k_tff.htm |
| 2024-03-27 | 8-K | 2024-03-27 | 7.01 Regulation FD Disclosure | 7.01 On March 27, 2024, the Company issued a press release and published an investor presentation on its website at https://tffpharma.com/investors/ and intends to utilize the presentation in connection with a clinical update call on March 27, 2024. | ea0202723-8k_tff.htm |
| 2024-03-22 | 8-K | 2024-03-20 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 The information contained above in Item 1.01 related to the Common Warrants and Wainwright Warrants and the shares of common stock issuable thereunder is incorporated herein by reference into this Item 3.02. 8.01 The Company issued press releases announcing the Offering and the closing of the Offering on March 20, 2024 and March 22, 2024, respectively. | ea0202366-8k_tffpharma.htm |
| 2023-12-19 | 8-K | 2023-12-15 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 5.03 On December 18, 2023, TFF Pharmaceuticals, Inc. (the “Company”) filed with the Delaware Secretary of State a Certificate of Amendment (“Amendment”) to its Second Amended and Restated Certificate of Incorporation to effect a one for twenty-five (25) reverse stock split (“Reverse Split”) of its issued and outstanding shares of common stock. 8.01 The Company has scheduled a webcast for December 19, 2023 at which it will discuss interim data readouts for its ongoing Phase 2 clinical trials of TFF VORI and TFF TAC. | ea190285-8k_tffpharma.htm |
| 2023-12-15 | 8-K | 2023-12-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 11, 2023, our Board of Directors, or Board, acting on the recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Thomas King to serve as a director of TFF Pharmaceuticals, Inc. until our next annual meeting of the stockholders and until his successor is elected and qualified or until his earlier resignation or removal. | ea190135-8k_tffpharm.htm |
| 2023-12-08 | 8-K | 2023-12-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 8, 2023, we elected not to renew the employment agreement of Christopher Cano as our Chief Operating Officer and Business Director. | ea189755-8k_tffpharma.htm |
| 2023-12-04 | 8-K | 2023-12-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 1, 2023, our Board of Directors, or Board, acting on the recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Catherine Lee and Michael Patane to serve as directors of TFF Pharmaceuticals, Inc. until our next annual meeting of the stockholders and until their respective successors are elected and qualified or until their earlier resignation or removal. | ea189274-8k_tffpharm.htm |
| 2023-11-22 | 8-K | 2023-11-21 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 5.03 On November 21, 2023, TFF Pharmaceuticals, Inc. filed with the Delaware Secretary of State an amendment to its Second Amended and Restated Certificate of Incorporation (“Certificate of Incorporation”) to increase its authorized common stock to 180 million shares. | ea188953-8k_tffpharm.htm |
| 2023-11-14 | 8-K | 2023-11-14 | 2.02 Results of Operations and Financial Condition | 2.02 On November 14, 2023, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023. | ea188313-8k_tffpharm.htm |
| 2023-09-18 | 8-K | 2023-08-30 | 7.01 Regulation FD Disclosure | 7.01 On August 30, 2023, TFF Pharmaceuticals, Inc. (“Company”) received a notice from the Nasdaq Stock Market, LLC (“Nasdaq”) stating that the staff of the Nasdaq has determined that the Company will be eligible for an additional 180 calendar day period to regain compliance with the minimum bid price requirement in Nasdaq listing Rule 5450(a)(1). | ea185369-8k_tffpharma.htm |
| 2023-09-18 | 8-K | 2023-09-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 13, 2023, Aaron Fletcher, Ph.D. advised the Board of Directors (“Board”) of TFF Pharmaceuticals, Inc. (“Company”) of his decision not to stand for reelection to the Board at the Company’s 2023 annual meeting of stockholders, to be held later this year. | ea185311-8k_tffpharma.htm |
| 2023-08-15 | 8-K | 2023-08-14 | 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 2.02 On August 15, 2023, the Company issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023. 7.01 Attached hereto as Exhibit 99.4 is a corporate update and presentation by the Company. | ea183413-8k_tffpharma.htm |
| 2023-06-23 | 8-K | 2023-06-23 | 8.01 Other Events | 8.01 On June 23, 2023, the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, awarded TFF Pharmaceuticals, Inc. (“Company”) a Direct to Phase II Small Business Innovation Research (“SBIR”) grant of approximately $2.97 million to continue development of a novel, pan-flu multivariant mucosal vaccine using the Company’s Thin Film Freezing technology. | ea180476-8k_tffpharma.htm |
| 2023-05-11 | 8-K | 2023-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2023, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2023. | ea178381-8k_tffpharma.htm |
| 2023-04-06 | 8-K | 2023-03-31 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On March 31, 2023, our Board of Directors approved and adopted our First Amended and Restated Bylaws (“Amended Bylaws”) of the Corporation. | ea176605-8k_tffpharma.htm |
| 2023-03-08 | 8-K | 2023-03-02 | 7.01 Regulation FD Disclosure | 7.01 On March 2, 2023, TFF Pharmaceuticals, Inc. (“Company”) received a notice of delisting (the “Notice”) from the Nasdaq Stock Market, LLC. | ea174799-8k_tffpharma.htm |
| 2023-03-07 | 8-K | 2023-03-07 | 2.02 Results of Operations and Financial Condition | 2.02 On March 7, 2023, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year and fiscal quarter ended December 31, 2022. | ea174819-8k_tffpharma.htm |
| 2023-02-17 | 8-K | 2023-02-16 | 8.01 Other Events | 8.01 On February 16, 2023, TFF Pharmaceuticals, Inc. conducted an investor call and presentation. | ea173875-8k_tffpharma.htm |
| 2023-02-16 | 8-K | 2023-02-16 | 7.01 Regulation FD Disclosure | 7.01 On February 16, 2023, TFF Pharmaceuticals, Inc. (the “Company”) published an investor presentation on its website at https://tffpharma.com/investors/. | ea173850-8k_tffpharma.htm |
| 2023-02-09 | 8-K | 2023-02-08 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On February 8, 2023, TFF Pharmaceuticals, Inc. held a Special Meeting of Stockholders, for the purposes of approving and adopting an amendment (the “Amendment”) to the Company’s Second Amended and Restated Certificate of Incorporation to effect an increase in the number of authorized shares of the Company’s common stock from 45,000,000 to 90,000,000. | ea173150-8k_tffpharma.htm |
| 2023-01-11 | 8-K | 2023-01-05 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 Entry into a Material Definitive Agreement. 5.02 On January 5, 2023, the Company appointed Zamaneh Mikhak, M.D. to serve as chief medical officer of the Company. | ea171529-8k_tffpharma.htm |
| 2022-12-08 | 8-K | 2022-12-04 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 Entry into a Material Definitive Agreement. 5.02 On December 4, 2022, Glenn Mattes resigned as president and chief executive officer and as a member of the board of directors, or Board, of the Company. | ea169866-8k_tffpharma.htm |
| 2022-11-18 | 8-K | 2022-11-17 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | ea169000-8k_tffpharma.htm |
| 2022-11-14 | 8-K | 2022-11-14 | 2.02 Results of Operations and Financial Condition | 2.02 On November 14, 2022, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022. | ea168613-8k_tffpharma.htm |
| 2022-11-08 | 8-K | 2022-11-07 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 • Electing six directors, each to serve until our 2023 Annual Meeting of Stockholders; and • Ratifying the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022. | ea168248-8k_tffpharma.htm |
| 2022-09-30 | 8-K | 2022-09-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | ea166616-8k_tffpharm.htm | |
| 2022-08-11 | 8-K | 2022-08-11 | 2.02 Results of Operations and Financial Condition | 2.02 On August 11, 2022, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2022. | ea164200-8k_tffpharm.htm |
| 2022-06-10 | 8-K | 2022-06-10 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | ea161325-8k_tffpharmace.htm |
| 2022-05-11 | 8-K | 2022-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2022, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2022. | ea159719-8k_tffpharmace.htm |
| 2022-03-24 | 8-K | 2022-03-24 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On March 24, 2022, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2021. 7.01 On March 24, 2022, the Company published an investor presentation on its website at https://ir.tffpharma.com/. | ea157352-8k_tffpharmace.htm |
| 2021-12-21 | 8-K | 2021-12-21 | 7.01 Regulation FD Disclosure | 7.01 On December 21, 2021, TFF Pharmaceuticals, Inc. (the “Company”) published an investor presentation on its website at https://ir.tffpharma.com/. | ea152828_8k-tffpharmace.htm |
| 2021-11-16 | 8-K | 2021-11-15 | 2.02 Results of Operations and Financial Condition | 2.02 On November 15, 2021, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2021. | ea150736-8k_tffpharmace.htm |
| 2021-11-10 | 8-K | 2021-11-04 | 5.07 Submission of Matters to a Vote of Security Holders | ea150362-8k_tffpharma.htm | |
| 2021-08-12 | 8-K | 2021-08-12 | 2.02 Results of Operations and Financial Condition | 2.02 On August 12, 2021, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2021. | ea145714-8k_tffpharma.htm |
| 2021-05-13 | 8-K | 2021-05-13 | 2.02 Results of Operations and Financial Condition | 2.02 On May 13, 2021, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2021. | ea140813-8k_tffpharma.htm |
| 2021-03-26 | 8-K | 2021-03-26 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On March 26, 2021, Lung Therapeutics, Inc. (“LTI”) also entered into the Agreement with the Underwriter, relating to an underwritten offering of 715,000 shares (“LTI Shares”) of Common Stock owned by LTI. | ea138463-8k_tffpharma.htm |
| 2021-03-10 | 8-K | 2021-03-10 | 2.02 Results of Operations and Financial Condition | 2.02 On March 10, 2021, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2020. | ea137397-8k_tffpharma.htm |
| 2020-12-04 | 8-K | 2020-12-04 | 8.01 Other Events | 8.01 On December 4, 2020, Lung Therapeutics, Inc. (“LTI”) entered into separate Common Stock Purchase Agreements with two institutional investors (the “Purchasers”), pursuant to which LTI agreed to sell to the Purchasers an aggregate of 550,000 shares (the “Shares”) of TFF Pharmaceuticals, Inc. common stock owned by LTI for a cash purchase price of $13.86 per share. | ea131083-8k_tffpharma.htm |
| 2020-12-04 | 8-K | 2020-12-04 | 8.01 Other Events | 8.01 On December 4, 2020, Lung Therapeutics, Inc. (“LTI”) entered into a Common Stock Purchase Agreement with an institutional investor (the “Purchaser”), pursuant to which LTI sold to the Purchaser 500,000 shares (the “Shares”) of TFF Pharmaceuticals, Inc. common stock owned by LTI for a cash purchase price of $13.85 per share. | ea131028-8k_tffpharma.htm |
| 2020-11-05 | 8-K | 2020-11-05 | 2.02 Results of Operations and Financial Condition | 2.02 On November 5, 2020, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2020. | ea129423-8k_tffpharma.htm |
| 2020-10-01 | 8-K | 2020-09-30 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 ● Ratifying the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020. | ea127673-8k_tffpharma.htm |
| 2020-09-30 | 8-K | 2020-09-24 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 Effective as of September 24, 2020, the Board of Directors (the “Board”) of TFF Pharmaceuticals, Inc. (the “Company”) appointed Christopher Cano to serve as the Chief Operating Officer and Vice President of Business Development of the Company. 5.02 Effective as of September 24, 2020, our Board, acting on the recommendation of the Board’s nominating and corporate governance committee, appointed Christopher Cano to serve as the Chief Operating Officer and Vice President of Business Development of TFF Pharmaceuticals, Inc. until his earlier death, resignation or removal. | ea127539-8k_tffpharma.htm |
| 2020-08-13 | 8-K | 2020-08-13 | 2.02 Results of Operations and Financial Condition | 2.02 On August 13, 2020, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2020. | ea125469-8k_tffpharmaceutic.htm |
| 2020-08-11 | 8-K | 2020-08-10 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. 8.01 The Company issued a press release on August 11, 2020 announcing the private placement. | ea125332-8k_tffpharma.htm |
| 2020-05-14 | 8-K | 2020-05-14 | 2.02 Results of Operations and Financial Condition | 2.02 On May 14, 2020, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2020. | ea121878-8k_tffpharma.htm |
| 2020-03-26 | 8-K | 2020-03-26 | 2.02 Results of Operations and Financial Condition | 2.02 On March 26, 2020, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2019. | ea120032-8k_tffpharma.htm |
| 2020-01-31 | 8-K | 2020-01-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 27, 2020, our board of directors, acting on the recommendation of the board’s nominating and corporate governance committee, appointed Malcolm Fairbairn to serve as a director of TFF Pharmaceuticals, Inc. until the next annual meeting of the stockholders of the company and until his successor is elected and qualified or until his earlier resignation or removal. | f8k012720_tffpharmaceuticals.htm |
| 2019-12-17 | 8-K | 2019-12-17 | 8.01 Other Events | 8.01 TFF Pharmaceuticals investors and others should note that we announce material information to the public about our company, technology, product candidates and other issues through a variety of means, including TFF Pharmaceuticals’ website, press releases, SEC filings and social media, in order to achieve broad, non-exclusionary distribution of information to the public. | f8k121719_tffpharma.htm |